These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22310589)

  • 41. One-Year Multicenter Double-Blind Randomized Clinical Trial on the Efficacy and Safety of Generic Cyclosporine (Iminoral) in De Novo Kidney Transplant Recipients.
    Khatami SM; Taheri S; Azmandian J; Sagheb MM; Nazemian F; Razeghi E; Shahidi S; Sadri F; Shamshiri AR; Sayyah M
    Exp Clin Transplant; 2015 Jun; 13(3):233-8. PubMed ID: 26086833
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.
    Larsen CP; Grinyó J; Medina-Pestana J; Vanrenterghem Y; Vincenti F; Breshahan B; Campistol JM; Florman S; Rial Mdel C; Kamar N; Block A; Di Russo G; Lin CS; Garg P; Charpentier B
    Transplantation; 2010 Dec; 90(12):1528-35. PubMed ID: 21076381
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year.
    Benigni A; Bruzzi I; Mister M; Azzollini N; Gaspari F; Perico N; Gotti E; Bertani T; Remuzzi G
    Kidney Int; 1999 Feb; 55(2):674-85. PubMed ID: 9987092
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine--results at six months after transplantation.
    Eisen HJ; Hobbs RE; Davis SF; Laufer G; Mancini DM; Renlund DG; Valantine H; Ventura H; Vachiery JL; Bourge RC; Canver CC; Carrier M; Costanzo MR; Copeland J; Dureau G; Frazier OH; Dorent R; Hauptman PJ; Kells C; Master R; Michaud JL; Paradis I; Smith A; Vanhaecke J; Mueller EA
    Transplantation; 1999 Sep; 68(5):663-71. PubMed ID: 10507486
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group.
    Pollard SG; Lear PA; Ready AR; Moore RH; Johnson RW
    Transplantation; 1999 Nov; 68(9):1325-31. PubMed ID: 10573071
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Conversion to generic cyclosporine A in stable chronic patients after heart transplantation.
    Kraeuter M; Helmschrott M; Erbel C; Gleissner CA; Frankenstein L; Schmack B; Ruhparwar A; Ehlermann P; Katus HA; Doesch AO
    Drug Des Devel Ther; 2013; 7():1421-6. PubMed ID: 24348018
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic monitoring of pediatric renal transplant patients with conversion to generic cyclosporin.
    Riva N; Guido PC; Ibañez J; Licciardone N; Rousseau M; Mato G; Monteverde M; Schaiquevich P
    Int J Clin Pharm; 2014 Aug; 36(4):779-86. PubMed ID: 24861769
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The efficacy and safety of ciclosporin (Equoral®) capsules after renal transplantation: A multicentre, open-label, phase IV clinical trial.
    Durlik M; Paczek L; Rutkowski B; Lewandowska D; Debska-Slizien A; Chamienia A; Wyzgal J; Ognista-Gajda A; Niemczyk M
    Ann Transplant; 2010; 15(3):51-9. PubMed ID: 20877267
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and effectiveness of microemulsion cyclosporine in renal allograft recipients: 1-year follow-up study.
    Park K; Kim MS; Kim SI; Kim YS; Moon JI
    Transplant Proc; 1998 Nov; 30(7):3556-7. PubMed ID: 9838557
    [No Abstract]   [Full Text] [Related]  

  • 50. Variability of cyclosporine exposure and its relevance to chronic allograft nephropathy: a case-control study.
    Stoves J; Newstead CG
    Transplantation; 2002 Dec; 74(12):1794-7. PubMed ID: 12499901
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation.
    Kovarik JM; Mueller EA; Richard F; Niese D; Halloran PF; Jeffery J; Paul LC; Keown PA
    Transplantation; 1996 Sep; 62(6):759-63. PubMed ID: 8824473
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Renal sodium transporters are increased in urinary exosomes of cyclosporine-treated kidney transplant patients.
    Esteva-Font C; Guillén-Gómez E; Diaz JM; Guirado L; Facundo C; Ars E; Ballarin JA; Fernández-Llama P
    Am J Nephrol; 2014; 39(6):528-35. PubMed ID: 24942911
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of the conventional and microemulsion formulations of cyclosporine in pancreas-kidney transplant recipients with gastroparesis.
    van der Pijl JW; Srivastava N; Denouël J; Burggraaf J; Schoemaker RC; van der Woude FJ; Cohen AF
    Transplantation; 1996 Aug; 62(4):456-62. PubMed ID: 8781610
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Maintenance immunosuppressive therapy and generic cyclosporine A use in adult renal transplantation: a single center analysis.
    Diarra DA; Riegersperger M; Säemann MD; Sunder-Plassmann G
    Kidney Int Suppl; 2010 Mar; (115):S8-11. PubMed ID: 20150906
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: a report of the Canadian Neoral Renal Study Group.
    Cole E; Keown P; Landsberg D; Halloran P; Shoker A; Rush D; Jeffrey J; Russell D; Stiller C; Muirhead N; Paul L; Zaltzman J; Loertscher R; Daloze P; Dandavino R; Boucher A; Handa P; Lawen J; Belitsky P; Parfrey P; Tan A; Hendricks L
    Transplantation; 1998 Feb; 65(4):505-10. PubMed ID: 9500624
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Results of a three-year prospective study of C2 monitoring in long-term renal transplant recipients receiving cyclosporine microemulsion.
    Citterio F; Scatà MC; Romagnoli J; Nanni G; Castagneto M
    Transplantation; 2005 Apr; 79(7):802-6. PubMed ID: 15818322
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factors predictive of medication nonadherence after renal transplantation: a French observational study.
    Couzi L; Moulin B; Morin MP; Albano L; Godin M; Barrou B; Alamartine E; Morelon E; Girardot-Seguin S; Mendes L; Misdrahi D; Cassuto E; Merville P
    Transplantation; 2013 Jan; 95(2):326-32. PubMed ID: 23149477
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Generic formulation of Cyclosporine A, Equoral®, in de novo kidney transplant recipients: five-year follow-up.
    Niemczyk M; Paczek L
    Ann Transplant; 2011; 16(2):59-62. PubMed ID: 21716187
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Microemulsion cyclosporine postmarketing surveillance in renal transplant recipients: multicenter study in Korea.
    Korean Neoral Study Group
    Transplant Proc; 2000 Nov; 32(7):1473-6. PubMed ID: 11119794
    [No Abstract]   [Full Text] [Related]  

  • 60. Cyclosporine and long-term kidney graft survival.
    Opelz G; Döhler B
    Transplantation; 2001 Oct; 72(7):1267-73. PubMed ID: 11602854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.